Piper Sandler Expands Board, Appoints New Independent Director

An announcement from Piper Sandler ( (PIPR) ) is now available.

Effective February 4, 2026, Piper Sandler Companies expanded its board of directors from nine to ten members and elected Stuart M. Essig as a director for an initial term ending at the firm’s 2026 annual meeting of shareholders, also appointing him to the Audit Committee. Essig, the longtime former chief executive and current chairman of Integra LifeSciences Corporation and a director at IDEXX Laboratories, will join Piper Sandler’s 2026 non-employee director compensation program, receiving a pro-rated cash retainer and equity awards, and the company noted there are no special arrangements or related-party transactions connected to his appointment, underscoring standard governance practices around the board refresh announced on February 4, 2026.

The most recent analyst rating on (PIPR) stock is a Hold with a $384.00 price target. To see the full list of analyst forecasts on Piper Sandler stock, see the PIPR Stock Forecast page.

Spark’s Take on PIPR Stock

According to Spark, TipRanks’ AI Analyst, PIPR is a Neutral.

Piper Sandler’s overall stock score is driven by strong financial performance and positive earnings call highlights, including record revenues and strategic growth in investment banking. However, technical indicators suggest bearish momentum, and valuation metrics indicate potential overvaluation. Cash flow management issues and external risks, such as a government shutdown, also weigh on the score.

To see Spark’s full report on PIPR stock, click here.

More about Piper Sandler

Piper Sandler Companies operates as an investment bank and financial services firm, providing advisory, underwriting and related capital markets services to corporate, institutional and public-sector clients.

Average Trading Volume: 125,004

Technical Sentiment Signal: Buy

Current Market Cap: $6.12B

See more insights into PIPR stock on TipRanks’ Stock Analysis page.